<DOC>
	<DOCNO>NCT00631592</DOCNO>
	<brief_summary>This repeat dose escalation study GSK1349572 follow relative bioavailability study compare tablet suspension formulation healthy volunteer .</brief_summary>
	<brief_title>GSK1349572 Repeat Dose Escalation Relative Bioavailability Study</brief_title>
	<detailed_description>ING111322 : A Double-Blind , Randomized , Placebo-Controlled , Repeat Dose Escalation Study Investigate Safety , Tolerability Pharmacokinetics GSK1349572 Followed A Single Dose , Randomized , 3-Period , Balanced , Crossover Study Assess Relative Bioavailability Two Formulations Food Effect GSK1349572 Healthy Male Female Subjects</detailed_description>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 50 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal documented bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy , Is postmenopausal defined 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 mlU/ml confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt , HRT discontinue 2 week subject rescreened , HRT suppress FSH . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication 14 day last dose study medication . Body weight &gt; / 50 kg men &gt; / 45 kg woman BMI within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . screen ECG within protocol parameter ( single repeat allow eligibility determination ) : â€¢ Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , WPW syndrome ) . Sinus Pauses &gt; 3 second . Any significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject . Nonsustained sustain ventricular tachycardia ( 3 consecutive ventricular ectopic beat ) . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , direct bilirubin creatinine value great upper limit normal . A single repeat allow eligibility determination . History significant renal hepatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>GSK1349572 ,</keyword>
	<keyword>healthy volunteer ,</keyword>
	<keyword>repeat dose ,</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>Healthy subject</keyword>
</DOC>